The company discontinued developing emugrobart after two studies showed the drug didn’t achieve intended outcomes.

Oppenheimer analyst Kostas Biliouris, meanwhile, said Sarepta's data in the programs "appear promising." ・The firm now awaits ...

Sarepta (SRPT) stock rises on positive Phase 1/2 siRNA trial data showing muscle delivery, biomarker activity, and safety in ...

When it comes to muscular diseases, most of us have heard of especially common ones like muscular dystrophy and Lou Gehrig's disease. But one of the rarest muscular disorders is also one of the most ...

The big pharma company will no longer progress emugrobart to late-stage trials in FSHD and SMA due to a lack of efficacy.

Chugai Pharmaceutical Co. fell 7.3%, the largest intraday decline since August 2025, after the company said it had ended the ...

A team at the Centro Nacional de Investigaciones Cardiovasculares (CNIC) has developed an innovative method known as TEVs-TTN, for studying the specific mechanical functions of proteins through their ...

Biomedical engineers have grown muscles in a lab to better understand and test treatments for a group of extremely rare muscle disorders called dysferlinopathy or limb girdle muscular dystrophies 2B ...

Therapies to target neuromuscular disorders affecting million of people worldwide are on the horizon thanks to research at the Montreal Clinical Research Institute of Montreal. Fusion of myoblasts, ...

Researchers in public health have reported in the first broad study in the United States the frequency of two muscle-weakness disorders that strike mostly boys: Duchenne muscular dystrophy and Becker ...